Mesoblast Limited's (ASX:MSB) 17% Gain Last Week Benefited Both Retail Investors Who Own 54% as Well as Insiders
JPMorgan Chase Takes Significant Stake in Mesoblast
Mesoblast Announces Director Change and Shareholdings
Mesoblast Limited's AGM Resolutions Gain Strong Approval
Mesoblast Director Joseph Swedish Steps Down
Mesoblast Limited Outlines Future Strategies and Growth Prospects
Mesoblast Limited Issues Unquoted Warrants in Strategic Move
Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $18
Buy Rating for Mesoblast Driven by Promising Market Opportunities and Upcoming PDUFA Date for Ryoncil
Express News | Mesoblast Ltd : Maxim Group Raises Target Price to $18 From $12
Mesoblast Posts Cash Balance of Over $51 Million in Fiscal Q1
Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $11
Press Release: Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
When Will Mesoblast Limited (ASX:MSB) Become Profitable?
Mesoblast Advances Cellular Medicines Amid FDA Hopes
6-K: Report of foreign private issuer (related to financial reporting)
Mesoblast Limited Schedules 2024 Annual General Meeting
Mesoblast Limited Enhances Corporate Governance Transparency
Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday
Mesoblast Shareholding Structure Altered